

Michael Saborowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/558638/publications.pdf>

Version: 2024-02-01

20
papers

1,976
citations

623734

14
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

5081
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2137-2144. | 2.5 | 1 |
| 2 | p53-Independent Induction of p21 Fails to Control Regeneration and Hepatocarcinogenesis in a Murine Liver Injury Model. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1387-1404. | 4.5 | 3 |
| 3 | The Coâ€mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusionâ€Driven Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1357-1370. | 7.3 | 13 |
| 4 | Generation of focal mutations and large genomic deletions in the pancreas using inducible <i>in vivo</i> genome editing. <i>Carcinogenesis</i> , 2020, 41, 334-344. | 2.8 | 7 |
| 5 | Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro. <i>Hepatology Communications</i> , 2019, 3, 423-436. | 4.3 | 25 |
| 6 | Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research. <i>Cancers</i> , 2019, 11, 1868. | 3.7 | 5 |
| 7 | Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. <i>Cancers</i> , 2019, 11, 1904. | 3.7 | 11 |
| 8 | CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713. | 5.4 | 351 |
| 9 | Clinical characteristics of patients with liver cirrhosis and spontaneous portosystemic shunts detected by ultrasound in a tertiary care and transplantation centre. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1107-1113. | 1.5 | 18 |
| 10 | Arid1a restrains Kras-dependent changes in acinar cell identity. <i>ELife</i> , 2018, 7, . | 6.0 | 39 |
| 11 | Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer. <i>Cell Reports</i> , 2016, 17, 2234-2246. | 6.4 | 57 |
| 12 | Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. <i>Gastroenterology</i> , 2016, 151, 338-350.e7. | 1.3 | 65 |
| 13 | Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. <i>Molecular Therapy</i> , 2015, 23, 1630-1640. | 8.2 | 165 |
| 14 | Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. <i>Genome Research</i> , 2015, 25, 714-724. | 5.5 | 115 |
| 15 | Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. <i>Science Translational Medicine</i> , 2015, 7, 271ra7. | 12.4 | 236 |
| 16 | Conditional Reverse Tet-Transactivator Mouse Strains for the Efficient Induction of TRE-Regulated Transgenes in Mice. <i>PLoS ONE</i> , 2014, 9, e95236. | 2.5 | 79 |
| 17 | A modular and flexible ESC-based mouse model of pancreatic cancer. <i>Genes and Development</i> , 2014, 28, 85-97. | 5.9 | 70 |
| 18 | Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor $\hat{1}^2$ Signaling. <i>Cell</i> , 2014, 157, 382-394. | 28.9 | 412 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors. <i>Cancer Cell</i> , 2014, 25, 697-710. | 16.8 | 238 |
| 20 | Mouse model of intrahepatic cholangiocarcinoma validates FIG ¹⁸ ROS as a potent fusion oncogene and therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19513-19518. | 7.1 | 66 |